Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC).

Widaplik is indicated for the treatment of hypertension, including as initial treatment, to lower blood pressure.

Individuals with recall related inquiries can contact Amneal Pharmaceuticals at (833) 582-0812 or via email at [email protected]. Adverse reactions should be reported to ...

Sonu, an AI-enabled wearable device, is now approved for use in pediatric patients aged 12 years and older for the relief of moderate to severe nasal ...